Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop

Author:

Cook Jonathan A1ORCID,Julious Steven A2ORCID,Sones William1,Hampson Lisa V3,Hewitt Catherine4,Berlin Jesse A5,Ashby Deborah6,Emsley Richard7,Fergusson Dean A8ORCID,Walters Stephen J2,Wilson Edward CF910,MacLennan Graeme11,Stallard Nigel12,Rothwell Joanne C2ORCID,Bland Martin13,Brown Louise14,Ramsay Craig R15,Cook Andrew16,Armstrong David17ORCID,Altman Douglas1,Vale Luke D18

Affiliation:

1. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

2. Medical Statistics Group, School of Health and Related Research, University of Sheffield, Sheffield, UK

3. Statistical Methodology and Consulting, Novartis Pharma AG, Basel, Switzerland

4. York Trials Unit, Department of Health Sciences, University of York, York, UK

5. Johnson & Johnson, Titusville, NJ, USA

6. Imperial Clinical Trials Unit, Imperial College London, London, UK

7. Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

8. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada

9. Cambridge Centre for Health Services Research, Cambridge Clinical Trials Unit University of Cambridge, Cambridge, UK

10. Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, UK

11. Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK

12. Warwick Medical School, Statistics and Epidemiology, University of Warwick, Coventry, UK

13. Department of Health Sciences, University of York, York, UK

14. MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK

15. Health Services Research Unit, University of Aberdeen, Aberdeen, UK

16. Wessex Institute, University of Southampton, Southampton, UK

17. School of Population Health and Environmental Sciences, King’s College London, London, UK

18. Health Economics Group, Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK

Abstract

Background The randomised controlled trial is widely considered to be the gold standard study for comparing the effectiveness of health interventions. Central to its design is a calculation of the number of participants needed (the sample size) for the trial. The sample size is typically calculated by specifying the magnitude of the difference in the primary outcome between the intervention effects for the population of interest. This difference is called the ‘target difference’ and should be appropriate for the principal estimand of interest and determined by the primary aim of the study. The target difference between treatments should be considered realistic and/or important by one or more key stakeholder groups. Objective The objective of the report is to provide practical help on the choice of target difference used in the sample size calculation for a randomised controlled trial for researchers and funder representatives. Methods The Difference ELicitation in TriAls2 (DELTA2) recommendations and advice were developed through a five-stage process, which included two literature reviews of existing funder guidance and recent methodological literature; a Delphi process to engage with a wider group of stakeholders; a 2-day workshop; and finalising the core document. Results Advice is provided for definitive trials (Phase III/IV studies). Methods for choosing the target difference are reviewed. To aid those new to the topic, and to encourage better practice, 10 recommendations are made regarding choosing the target difference and undertaking a sample size calculation. Recommended reporting items for trial proposal, protocols and results papers under the conventional approach are also provided. Case studies reflecting different trial designs and covering different conditions are provided. Alternative trial designs and methods for choosing the sample size are also briefly considered. Conclusions Choosing an appropriate sample size is crucial if a study is to inform clinical practice. The number of patients recruited into the trial needs to be sufficient to answer the objectives; however, the number should not be higher than necessary to avoid unnecessary burden on patients and wasting precious resources. The choice of the target difference is a key part of this process under the conventional approach to sample size calculations. This document provides advice and recommendations to improve practice and reporting regarding this aspect of trial design. Future work could extend the work to address other less common approaches to the sample size calculations, particularly in terms of appropriate reporting items. Funding Funded by the Medical Research Council (MRC) UK and the National Institute for Health Research as part of the MRC–National Institute for Health Research Methodology Research programme.

Funder

Health Technology Assessment programme

Medical Research Council

Publisher

National Institute for Health Research

Subject

Health Policy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3